Sunil S Patel, David R Lally, Jason Hsu, Charles C Wykoff, David Eichenbaum, Jeffrey S Heier, Glenn J Jaffe, Keith Westby, Dhaval Desai, Liansheng Zhu, Arshad M Khanani
BACKGROUND/OBJECTIVES: To assess the safety and efficacy of avacincaptad pegol (ACP), a C5 inhibitor, for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) over an 18-month treatment course. SUBJECTS/METHODS: This study was an international, prospective, randomized, double-masked, sham-controlled, phase 2/3 clinical trial that consisted of 2 parts. In part 1, 77 participants were randomized 1:1:1 to receive monthly intravitreal injections of ACP 1 mg, ACP 2 mg, or sham...
March 24, 2023: Eye